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Introduction: Rifampicin is one of the most effective antibiotics for treating tuberculosis, but it has been associated
with adverse reactions, such as nephrotoxicity, sometimes resulting in acute renal failure with oligoanuria, and
hepatotoxicity. Although deterioration of renal function, determined by acute tubulointerstitial nephritis and/or
acute tubular necrosis, typically appears in patients receiving intermittent rifampicin therapy, some authors have
also reported cases occurring during continuous rifampicin therapy.
Case presentation: We describe the case of acute renal failure with polyuria occurring in a previously healthy
50-year-old Caucasian man undergoing continuous therapy with rifampicin for culture-confirmed pulmonary
tuberculosis. The patient was admitted to the L. Spallanzani National Institute for Infectious Diseases, Rome, Italy,
with a 1-month history of coughing, fever and weight loss. After 6 weeks of standard antituberculous treatment,
progressive deterioration of his renal function was observed: creatinine levels rose from 38.9μmol/L to 318.2μmol/L
and urine volume also progressively increased to reach a state of true polyuria (8 to 10L of urine per day). He was
diagnosed with suspected acute rifampicin-induced renal failure. A renal biopsy showed focal segmental
glomerulosclerosis associated with acute tubulointerstitial nephritis. Rifampicin was discontinued with excellent
results: after 15 days his renal function began to improve and his serum creatinine values returned to normal.
Conclusion: A high index of suspicion for rifampicin-associated acute renal failure should be maintained in patients
with pulmonary tuberculosis who develop progressive deterioration of renal function during treatment with rifampicin.
Early diagnosis and discontinuation of rifampicin are of fundamental importance for recovering renal function.
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Rifampicin is one of the most effective antibiotics used
for treating tuberculosis, but it has been associated with
adverse reactions such as nephrotoxicity [1-4], some-
times resulting in acute renal failure (ARF), and hepato-
toxicity [1,2]. Although deterioration of renal function,
determined by acute tubulointerstitial nephritis and/or
acute tubular necrosis, typically appears in patients re-
ceiving intermittent rifampicin therapy, some authors
have also reported cases occurring during continuous* Correspondence: silvia.rosati@inmi.it
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reproduction in any medium, provided the orrifampicin therapy [1-4]. Retrospective studies have been
made to assess the prevalence, and the clinical and bio-
chemical features, of ARF following rifampicin treatment
[4-6]. ARF related to administration of rifampicin is gen-
erally associated with oligoanuria, whereas our patient
showed polyuria.
We describe a case of ARF with polyuria occurring in
a patient receiving continuous administration of rifampi-
cin for pulmonary tuberculosis; biopsy findings revealed
focal segmental glomerulosclerosis associated with acute
tubulointerstitial nephritis.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Time relationship between rifampicin treatment,
serum creatinine level and glomerular filtration rate. W2/W6/
W8: 2/6/8 weeks of rifampicin treatment; W-2: 2 weeks after
discontinuing rifampicin treatment. GFR; Glomerular filtration rate.
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A previously healthy 50-year-old Caucasian man was ad-
mitted to the L. Spallanzani National Institute for Infec-
tious Diseases in Rome, Italy, with a 1-month history of
coughing, fever and weight loss. Chest radiography dem-
onstrated “extensive upper right subclavian and apex left
subclavian infiltrates with cavitation” (Figure 1). Sputum
samples showed numerous acid-fast bacilli and ribo-
nucleic acid amplification-based assay from induced spu-
tum was positive for Mycobacterium tuberculosis and
the culture later grew susceptible M. tuberculosis. The
purified protein derivative skin test was reactive (10mm).
The patient tested negative for human immunodefi-
ciency virus. He began therapy with daily rifampicin
(600mg), isoniazid (300mg), pyrazinamide (1500mg) and
ethambutol (1200mg). Results of initial laboratory test-
ing including complete blood count, electrolytes and
liver and kidney function tests were within normal
ranges. On day 42 after admission (still sputum-smear
positive), progressive deterioration of renal function
was observed. Creatinine levels progressively rose from
38.9μmol/L on admission to 318.2μmol/L (normal, 44.2
to 123.7μmol/L), with a creatinine clearance of 18mL/
minute (Figure 2) and an increase of urinary sodium
(Na+ 285mEq/24hours). Urine volume also progressively
increased to reach a state of a true polyuria (8 to10 L of
urine per day). Urine examination results were signifi-
cant, showing 300mg/L of protein with a total excretion
of 2500 to 4000mg of protein/day, 200mg/dL of glucose
with a total excretion of 1.6 to 2.1g of glucose/day, 50 to
60 white blood cells/high power field and sterile
leukocyturia (with sterile urine culture), considered a
marker of interstitial nephritis. No eosinophils were
present in the urine: specific weight was 1005 to 1007. A
blood test indicated a hemoglobin level of 8.70g/dLFigure 1 Posteroanterior chest radiography: extensive upper
right subclavian and apex left subclavian infiltrates
with cavitation.(normal, 12 to 18g/dL), platelet count of 522 × 103/μL
(normal, 80 to 400 103/μL), blood urea nitrogen of
0.29mmol/L (normal, 0.04 to 0.18mmol/L) and serum
creatinine of 318.2μmol/L. He began modified antituber-
culous treatment consisting of isoniazid 300mg once
daily, pyrazinamide 1500mg three times weekly, etham-
butol 1000mg three times weekly, rifampicin 600mg
once daily and moxifloxacin (400mg once daily) but his
renal function did not improve. Venous blood gas
analysis showed metabolic acidosis (pH 7.30, bicarbonate
19mmol/L, base excess −5) and hypokalemia (K+
2.8mEq/L). Immunoglobulin testing of the serum
showed an increase of immunoglobulin As and immuno-
globulin Gs; anti-double stranded deoxyribonucleic acid
(DNA) antibodies were positive (1:160), antinuclear anti-
bodies were negative and complement factors C3 and
C4 levels were normal. Abdominal ultrasonography
showed “. . .kidney increased in volume, with disappear-
ance of the normal cortico-medullary differentiation. . .”.
The patient was treated with 7 to 8L/day of liquids via
intravenous infusion; acidosis and hypokalemia were
corrected and erythropoietin was administered for
anemia. On day 55, his serum creatinine was 358.9μmol/
L, blood urea nitrogen was 0.25mmol/L and polyuria
persisted. Serum test results for the antidiuretic
hormone were within the normal range. Based on previ-
ous reports of similar cases, a diagnosis of suspected
acute rifampicin-induced renal failure was made. A
renal biopsy showed focal segmental glomeruloscle-
rosis associated with acute tubulointerstitial nephritis
(Figure 3a-3b). Rifampicin was discontinued and the
response was excellent: no further therapy was required
(steroids or hemodialysis). Renal function began to im-
prove and 15 days after discontinuing rifampicin, serum
a b
Figure 3 Histology of renal biopsy (periodic Schiff-methenamine staining on a semi-thin section). (a) Glomerulus with a moderate, initial
segmental sclerotic (arrow) lesion (400× magnification). (b) Intense interstitial inflammation with lymphocytes and granulocytes (arrow) showing
invasion and focal destruction of the tubular epithelium (200× magnification).
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polyuria gradually regressed and after 20 days, diuresis
and venous blood gas analysis returned to normal.Discussion
There is currently a greater prevalence of acute post-
rifampicin renal failure due to the high spread of tuber-
culosis. ARF usually occurs in patients who receive
intermittent regimens (two or three times weekly), but
some authors have reported [1-4] ARF after daily treat-
ments. Retrospective studies have been made to assess
the prevalence, and the clinical and biochemical features,
of ARF following rifampicin treatment [4-6]. ARF related
to administration of rifampicin is generally associated
with oligoanuria, whereas our patient showed polyuria.
Various mechanisms of rifampicin-associated ARF have
been postulated [6] and it is difficult to determine the
incidence of ARF among all patients treated with rifam-
picin. The mechanism of renal damage is thought to be
due to allergic reactions to rifampicin or one of its me-
tabolites causing allergic interstitial nephritis. Immuno-
genicity of rifampicin has been demonstrated by the
presence of rifampicin-dependent antibodies in serum,
especially immunoglobulin M [6-9], but the relationship
between anti-rifampicin antibodies and the development
of renal failure is not clear; circulating rifampicin-
dependent antibodies have been observed in patients on
treatment with rifampicin without any evidence of renal
disease [8]. Conversely, not all patients on treatment
with rifampicin who develop renal failure have demon-
strable circulating antibodies [10]. Our patient showed
focal segmental glomerulosclerosis associated with se-
vere acute tubulointerstitial nephritis with polyuria
which regressed upon discontinuation of the drug. There
was no need for therapy with corticosteroids or
hemodialysis treatment. No cases of polyuria are repor-
ted in the data supplied by the literature or retrospective
studies.Conclusion
Acute interstitial nephritis is becoming an important cause
of acute, but reversible, renal failure and drug hypersensi-
tivity is the most common and important etiological factor
for this condition. The pathogenesis of tubular necrosis
has not yet been defined. Renal biopsy is the “gold stand-
ard” for the diagnosis. A high index of suspicion for
rifampicin-associated ARF should be maintained in pa-
tients with pulmonary tuberculosis who develop progres-
sive deterioration of renal function during treatment with
rifampicin. Early diagnosis and discontinuation of rifampi-
cin are of fundamental importance for recovering renal
function. We believe that the description of this case may
contribute to clinical experience due to the peculiarity of
the relation between the development of polyuria and
administration of rifampicin.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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